By Karen Blum
CHICAGO—Value-based contracts (VBCs) can provide opportunities for manufacturers to evaluate clinically appropriate outcomes not studied in clinical trials, while offering attractive pricing for payors, speakers said during a panel discussion at the AMCP 2022 annual meeting. They offered insight into this continuing evolving marketplace and advice for plans on how to pursue such contracts.
APRIL 1, 2022